Lilly lifts 2026 sales outlook $2 billion as Mounjaro revenue jumps 125%
First-quarter revenue reached $19.80 billion, and Lilly said it held 60.1% of the US obesity and diabetes drug market against Novo Nordisk's 39.4%.
The wire
- 01Mounjaro worldwide revenue rose 125% to $8.66 billion in the first quarter and Zepbound posted $4.16 billion in US sales, up 80%; guidance moved to $82-85 billion.
- 02Volume growth of 49% in the US came alongside lower realized prices for Zepbound, a signal for cash-pay clinics and telehealth operators tracking incretin pricing.
- 03CEO Dave Ricks tied the 81% jump in non-US revenue to launches in Europe, China and Brazil where many patients pay out of pocket; Lilly shares rose more than 10%.
From the source
Read at cnbc.comEli Lilly blows past quarterly estimates, hikes outlook as Zepbound and Mounjaro sales skyrocket
Eli Lilly on Thursday reported first-quarter earnings and revenue that blew past estimates and hiked its full-year sales outlook by $2 billion, as demand for its blockbuster weight loss drug Zepbound and diabetes treatment Mounjaro spiked again.